TriangleDISEASE & TREATMENT SETTING
SUTENT: recurrent Renal cell carcinoma (adjuvant) after prior therapy
Source-derived catalogue. This is not a treatment recommendation or a personalised trial match.
Exact scope
1.3 Adjuvant Treatment of Renal Cell Carcinoma SUTENT is indicated for the adjuvant treatment of adult patients at high risk of recurrent RCC following nephrectomy.
Broader topic: Renal Cell Cancer
- Source population
- Not part of this definition
- Disease extent
- recurrent
- Treatment line
- adjuvant
- Stage
- Not part of this definition
- Resectability
- Not part of this definition
Biomarkers, prior therapy and derivation
- molecular
- prior therapy
- class
- following nephrectomy
- status
- required
- derivation status
- source-attested
- derivation note
- Scoped from the FDA approved indication for SUTENT (product label). Only dimensions stated in that wording are part of this definition.
- source wording
- 1.3 Adjuvant Treatment of Renal Cell Carcinoma SUTENT is indicated for the adjuvant treatment of adult patients at high risk of recurrent RCC following nephrectomy.
Study evidence for this setting
18F-FPPRGD2 PET/CT or PET/MRI in Predicting Early Response in Patients With Cancer Receiving Anti-Angiogenesis Therapy
Molecular-Guided Therapy for Childhood Cancer
Health Care Coach Support in Reducing Acute Care Use and Cost in Patients With Cancer
Canady Helios Cold Plasma Scalpel Treatment at the Surgical Margin and Macroscopic Tumor Sites
Testing the Combination of the Anti-cancer Drugs XL184 (Cabozantinib) and Nivolumab in Patients With Advanced Cancer and HIV
Source relationships and population-mapping limitations
- bindings
- mappings
Download this complete draft source relationship record →
Preserved source evidence · Not medical advice